295 related articles for article (PubMed ID: 18998753)
1. Targeting nerve growth factor in pain: what is the therapeutic potential?
Watson JJ; Allen SJ; Dawbarn D
BioDrugs; 2008; 22(6):349-59. PubMed ID: 18998753
[TBL] [Abstract][Full Text] [Related]
2. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.
Eibl JK; Strasser BC; Ross GM
Neurochem Int; 2012 Dec; 61(8):1266-75. PubMed ID: 23103525
[TBL] [Abstract][Full Text] [Related]
3. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management.
McKelvey L; Shorten GD; O'Keeffe GW
J Neurochem; 2013 Feb; 124(3):276-89. PubMed ID: 23157347
[TBL] [Abstract][Full Text] [Related]
4. NGF receptor TrkAd5: therapeutic agent and drug design target.
Dawbarn D; Fahey M; Watson J; Tyler S; Shoemark D; Sessions R; Zhang R; Brady L; Willis C; Allen SJ
Biochem Soc Trans; 2006 Aug; 34(Pt 4):587-90. PubMed ID: 16856868
[TBL] [Abstract][Full Text] [Related]
5. NGF/TrkA Signaling as a Therapeutic Target for Pain.
Hirose M; Kuroda Y; Murata E
Pain Pract; 2016 Feb; 16(2):175-82. PubMed ID: 26452158
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factor.
Liu S; Shen Y; Chen P; Guo C; Zhang G; Jiang X; He J; Yang J
Protein Expr Purif; 2022 Jan; 189():105966. PubMed ID: 34627999
[TBL] [Abstract][Full Text] [Related]
7. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.
Ugolini G; Marinelli S; Covaceuszach S; Cattaneo A; Pavone F
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2985-90. PubMed ID: 17301229
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of nerve growth factor-TrkA signaling and the relief of pain.
Mantyh PW; Koltzenburg M; Mendell LM; Tive L; Shelton DL
Anesthesiology; 2011 Jul; 115(1):189-204. PubMed ID: 21602663
[TBL] [Abstract][Full Text] [Related]
9. Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA.
Rende M; Brizi E; Conner J; Treves S; Censier K; Provenzano C; Taglialatela G; Sanna PP; Donato R
Int J Dev Neurosci; 2000 Dec; 18(8):869-85. PubMed ID: 11154856
[TBL] [Abstract][Full Text] [Related]
10. Analgesia via blockade of NGF/TrkA signaling does not influence fracture healing in mice.
Rapp AE; Kroner J; Baur S; Schmid F; Walmsley A; Mottl H; Ignatius A
J Orthop Res; 2015 Aug; 33(8):1235-41. PubMed ID: 25876530
[TBL] [Abstract][Full Text] [Related]
11. Novel class of pain drugs based on antagonism of NGF.
Hefti FF; Rosenthal A; Walicke PA; Wyatt S; Vergara G; Shelton DL; Davies AM
Trends Pharmacol Sci; 2006 Feb; 27(2):85-91. PubMed ID: 16376998
[TBL] [Abstract][Full Text] [Related]
12. Swedish Nerve Growth Factor Mutation (NGF
Sung K; Ferrari LF; Yang W; Chung C; Zhao X; Gu Y; Lin S; Zhang K; Cui B; Pearn ML; Maloney MT; Mobley WC; Levine JD; Wu C
J Neurosci; 2018 Apr; 38(14):3394-3413. PubMed ID: 29483280
[TBL] [Abstract][Full Text] [Related]
13. Neurobiology of pain, interoception and emotional response: lessons from nerve growth factor-dependent neurons.
Indo Y
Eur J Neurosci; 2014 Feb; 39(3):375-91. PubMed ID: 24494678
[TBL] [Abstract][Full Text] [Related]
14. Nerve growth factor & TrkA as novel therapeutic targets in cancer.
Demir IE; Tieftrunk E; Schorn S; Friess H; Ceyhan GO
Biochim Biophys Acta; 2016 Aug; 1866(1):37-50. PubMed ID: 27264679
[TBL] [Abstract][Full Text] [Related]
15. Development of a pharmacodynamic biomarker to measure target engagement from inhibition of the NGF-TrkA pathway.
Price EA; Krasowska-Zoladek A; Nanda KK; Stachel SJ; Henze DA
J Neurosci Methods; 2017 Apr; 282():34-42. PubMed ID: 28279735
[TBL] [Abstract][Full Text] [Related]
16. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
Bannwarth B; Kostine M
Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
[TBL] [Abstract][Full Text] [Related]
17. Airway hyper-responsiveness in allergic asthma in guinea-pigs is mediated by nerve growth factor via the induction of substance P: a potential role for trkA.
de Vries A; Engels F; Henricks PA; Leusink-Muis T; McGregor GP; Braun A; Groneberg DA; Dessing MC; Nijkamp FP; Fischer A
Clin Exp Allergy; 2006 Sep; 36(9):1192-200. PubMed ID: 16961720
[TBL] [Abstract][Full Text] [Related]
18. Nerve growth factor and the physiology of pain: lessons from congenital insensitivity to pain with anhidrosis.
Indo Y
Clin Genet; 2012 Oct; 82(4):341-50. PubMed ID: 22882139
[TBL] [Abstract][Full Text] [Related]
19. The role of nerve growth factor in neuropathic pain inhibition produced by resiniferatoxin treatment in the dorsal root ganglia.
Tender GC; Li YY; Cui JG
Neurosurgery; 2013 Jul; 73(1):158-65; discussion 165-6. PubMed ID: 23615109
[TBL] [Abstract][Full Text] [Related]
20. Modulation of neurotrophin signaling by monoclonal antibodies.
Rosenthal A; Lin JC
Handb Exp Pharmacol; 2014; 220():497-512. PubMed ID: 24668485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
